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A C9ORF72 BAC mouse model recapitulates
key epigenetic perturbations of ALS/FTD
Rustam Esanov1, Gabriela Toro Cabrera2, Nadja S. Andrade1, Tania F. Gendron3, Robert H. Brown Jr.2,
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Abstract
Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal and progressive neurodegenerative disorder with
identified genetic causes representing a significant minority of all cases. A GGGGCC hexanucleotide repeat
expansion (HRE) mutation within the C9ORF72 gene has recently been identified as the most frequent known
cause of ALS. The expansion leads to partial heterochromatinization of the locus, yet mutant RNAs and dipeptide
repeat proteins (DPRs) are still produced in sufficient quantities to confer neurotoxicity. The levels of these toxic HRE
products positively correlate with cellular toxicity and phenotypic severity across multiple disease models. Moreover, the
degree of epigenetic repression inversely correlates with some facets of clinical presentation in C9-ALS patients.
Recently, bacterial artificial chromosomes (BAC) have been used to generate transgenic mice that harbor the HRE
mutation, complementing other relevant model systems such as patient-derived induced pluripotent stem cells (iPSCs).
While epigenetic features of the HRE have been investigated in various model systems and post-mortem tissues,
epigenetic dysregulation at the expanded locus in C9-BAC mice remains unexplored.
Methods and Results: Here, we sought to determine whether clinically relevant epigenetic perturbations caused by
the HRE are mirrored in a C9-BAC mouse model. We used complementary DNA methylation assessment and
immunoprecipitation methods to demonstrate that epigenetic aberrations caused by the HRE, such as DNA and
histone methylation, are recapitulated in the C9-BAC mice. Strikingly, we found that cytosine hypermethylation within
the promoter region of the human transgene occurred in a subset of C9-BAC mice similar to what is observed in
patient populations. Moreover, we show that partial heterochromatinization of the C9 HRE occurs during the first weeks
of the mouse lifespan, indicating age-dependent epigenetic repression. Using iPSC neurons, we found that preventing
R-loop formation did not impede heterochromatinization of the HRE.
Conclusions: Taken together, these observations provide further insight into mechanism and developmental
time-course of epigenetic perturbations conferred by the C9ORF72 HRE. Finally, we suggest that epigenetic
repression of the C9ORF72 HRE and nearby gene promoter could impede or delay motor neuron degeneration in
C9-BAC mouse models of ALS/FTD.
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Background
A pathological GGGGCC hexanucleotide repeat expan-
sion mutation located within the non-coding portion of
the C9ORF72 gene has been identified as the cause of
chromosome 9p21-linked ALS and frontotemporal de-
mentia (FTD) [1, 2]. The discovery places ALS and FTD
among a large family of nearly 40 repeat expansion disor-
ders, many of which specifically affect neurons [3]. The
C9ORF72 HRE is hypothesized to confer cytotoxicity, in
part, via RNA gain of function whereby sense and anti-
sense transcripts harboring the repeat sequester RNA
binding proteins resulting in ribonucleoprotein foci [4, 5],
preventing the proteins from carrying out their normal
function. In addition, expanded RNAs and dipeptide-
repeat proteins that arise from aberrant translation of mu-
tant RNAs disrupt nucleocytoplasmic transport [6–8].
Given that mutant RNAs and the DPRs derived from
them are the primary source of pathology in C9-ALS and
epigenetic mechanisms regulate their production, it
follows that epigenetic regulation of expanded C9ORF72
alleles is of particular significance.
Epigenetic alterations occur in many repeat expansion
disorders and there is now definitive evidence that epi-
genetic perturbations associated with the C9ORF72 HRE
contribute to C9-ALS pathophysiology [9–11]. Expanded
C9ORF72 alleles have reduced transcription rates, are
depleted of active histone marks with concomitant
enrichment of repressive epigenetic marks, including
DNA hypermethylation in some cases. Specifically, the
levels of all three C9ORF72 transcript variants are
reduced in C9-ALS, including variant 2 which does not
contain the repeat sequence due to alternative transcrip-
tion start site (TSS) utilization [1, 5, 12]. Enriched
repressive epigenetic marks include tri-methylation of
histone 3 at lysine positions 9 and 27 (H3K9me3,
H3K27me3) and histone 4 lysine 20 (H4K20me3) [12].
In addition, DNA methylation of cytosine residues
within CpG islands near the C9ORF72 promoter occurs
in approximately 30% of patients [13–15]. Notably, pro-
moter hypermethylation is theorized to be protective
due to decreased production of toxic products in patient
cells [16] leading to reduced neuronal loss in the brain
[17]. Mechanistically, DNA hypermethylation is
counteracted by active DNA demethylation [18] while
repeat instability is conferred by highly stable GC-rich
RNA-DNA duplex formation across the HRE [19]. In
addition to repeat instability, RNA-DNA hybrid struc-
tures, or R-loops, may also contribute to C9ORF72
hypermethylation. Indeed, R-loops are known to regulate
DNA methylation at CpG islands of gene promoters
including those affected by repeat expansion mutations
[20, 21]. Taken together, these observations indicate that
the C9ORF72 HRE alters the local epigenetic environ-
ment such that the rate of transcription, DNA
methylation, histone modification and R-loop formation
are all perturbed by the expansion mutation.
Two independent groups were first to develop trans-
genic mouse models of C9-ALS carrying the pathogenic
C9ORF72 HRE [22, 23]. The human repeat expansion
sequence was introduced into the mouse genome using
a bacterial artificial chromosome (BAC). The C9-BAC
mice displayed typical histopathological gain-off-
function features of C9-ALS including RNA foci and
DPR aggregates, yet no motor or cognitive phenotypes
were observed. Subsequently, two additional groups gen-
erated C9-BAC mice that exhibit reduced survival,
motor deficits and cognitive dysfunction [24, 25]. While
these previous reports focused on the production of
toxic HRE products, none have described epigenetic fea-
tures of the C9ORF72 transgene. Notably, the number of
toxic mRNA foci and DPR abundance in C9-BAC mice
was observed to significantly decline as a function of age
[23]. This is somewhat counter-intuitive since ALS/FTD
are age-related disorders. Therefore, we hypothesized
that partial epigenetic repression of the C9ORF72 trans-
gene could potentially attenuate the severity of pheno-
types in C9-BAC mice, limiting their applicability to
human disease. Herein, we performed a post-natal devel-
opmental study using transgenic BAC mice reported by
Peters et al. [23] to systematically investigate whether
characteristic epigenetic features of the HRE in C9-ALS
are recapitulated in this mouse model system.
Methods
C9-BAC mice
Animals used in the present study have previously been
described [23]. Briefly, a BAC containing human
sequence from a C9-ALS patient, spanning the gene
promoter to exon 6, was inserted into the mouse
genome using standard transgenic methods. All experi-
mental procedures involving transgenic mice were per-
formed in accordance with the guidelines of Institutional
Animal Care and Use Committee of the University of
Massachusetts Medical School.
DNA and RNA extraction
Genomic DNA and total RNA extractions were per-
formed from 30 mg of mouse brain tissues using a kit
(AllPrep DNA/RNA Mini Kit®, Qiagen #80204) as per
manufacturers’ instructions.
Quantitative PCR (qPCR)
Reactions were performed using TaqMan® assays that
amplify C9ORF72 transcript variants V1, V2, V3
(Hs00376619_m1), C9ORF72 V1, V3 (Hs00331877_m1),
C9ORF72 V2 (NM_018325.3, L/R/Probe: 5’CGGT
GGCGAGTGGATATCTC / 5’TGGGCAAAGAGTC
GACATCA/ 5’TAATGTGACAGTTGGAATGC), mouse
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Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(Mm99999915_g1), beta-actin (Mm00607939_s1), eukaryotic
18S ribosomal RNA (Hs99999901_s1) and human
GAPDH (Hs02758991_g1). Relative quantification
values were calculated using a standard curve method,
normalized to the average of GAPDH and 18S endogen-
ous control genes.
Digital droplet PCR (ddPCR)
For gene expression, 500 ng of total RNA was used in a
20 μl reaction to generate complementary DNA (cDNA)
using random hexamer primers and MultiScribe reverse
transcriptase (High capacity RNA-to-cDNA Kit, Life
Technologies). After diluting the cDNA 1:1.25, 2 μl were
loaded into a 20 μl reaction containing ddPCR Supermix
for Probes (nodUTP) (Bio-Rad, Gladesville, NSW,
Australia), and 1 μl of primers amplifying all three
C9ORF72 transcripts (Hs00376619_m1, Life Technolo-
gies). The 20 μl sample, along with 70 μl of ddPCR-oil
was loaded into a DG8 cartridge and covered with a gas-
ket according to manufacturer’s instructions; the cart-
ridge was then placed in a QX100 droplet generator.
40 μl of sample were then transferred to a 96-well PCR
plate and put in a normal PCR thermocycler (Eppendorf,
North Ryde, NSW, Australia). The plate was then placed
in the QX100 ddPCR reader (Bio-Rad, Gladesville,
NSW, Australia) for absolute quantification.
Methylation-sensitive quantitative PCR
DNA methylation at the C9ORF72 promoter was assessed
using previously reported methods [26]. Briefly, 100 ng
of genomic DNA was used for methylation-sensitive re-
striction digest with four units of HhaI endonuclease.
Two sets of primers were used for subsequent quantita-
tive PCR: C9me (L/R: 5’CGGTAAAAACAAAATT
TCATCCA / 5’GGGCAACTTGTCCTGTTCTT) spans
two HhaI restriction sites within the C9ORF72 pro-
moter, and C9ec (L/R: 5’AGGAAAGAGAGGTGCGT
CAA / 5’TCCTAAACCCACACCTGCTC) was used as
an endogenous control.
Bisulfite pyrosequencing
Genomic DNA (2 μg) was treated with bisulfite and ana-
lyzed by pyrosequencing (EpigenDx Inc.) as previously
reported [18]. The DNA methylation assessment was
performed using the PSQTM96HS system and custom
assays developed by EpigenDx (ADS3232-FS1 and
ADS3232-FS2). The assay covers 16 cytosine residues
within the C9ORF72 promoter from −55 to +125 base
pairs relative to the C9ORF72 transcriptional start site.
Copy Number Variation (CNV) analysis
C9ORF72 mouse brains were fresh frozen and cut in a
sagittal section to extract DNA. The tissue was lysed
overnight at 55 °C, RNAse treated and eluted following
manufacturer’s instructions (Gentra Puregene Tissue Kit,
Qiagen). The DNA was diluted to 20 ng/μl and 2 μl were
added to the ddPCR master mix along with 1 μl of each
primer/probe. Primer and probe sequences used for hu-
man genomic C9ORF72 (L/R/Probe: 5’AAGGCACAGA
GAGAATGGAAG / 5’AGGCTTATTCGTATGTCTCCA
AG / 5’AGGTTGATGGCTACATTTGTCAAGGC) and
for mouse EIF2C1 diploid genome (L/R/Probe: 5’C
CTGCCATGTGGAAGATGAT / 5’GAGTGTGGTGGC
TGGATTTA / 5’TGGGGAGAGCTGGAGCCAG) quan-
tification are indicated. Droplets were generated followed
by PCR and absolute quantification.
Poly(GP) immunoassay
C9-BAC whole brain tissues were lyzed in buffer con-
taining 50 mM Tris–HCl, pH 7.4, 300 mM NaCl, 1%
Triton X-100, 2% sodium dodecyl sulfate, 5 mM EDTA,
as well as protease (EMD Millipore) and phosphatase in-
hibitors (Sigma-Aldrich). After sonication, samples were
centrifuged at 16,000 x g for 20 min at 4 °C and super-
natants collected. The protein concentration of lysates
was determined by BCA assay (Thermo Scientific).
Poly(GP) levels in lysates were measured using a previ-
ously described sandwich immunoassay that utilizes
Meso Scale Discovery (MSD) electrochemiluminescence
detection technology [27]. Lysates were diluted in Tris-
buffered saline (TBS) and tested using 43 μg of protein
per well in duplicate wells. Serial dilutions of recombin-
ant (GP)8 in TBS were used to prepare the standard
curve. Response values corresponding to the intensity of
emitted light upon electrochemical stimulation of the
assay plate using the MSD QUICKPLEX SQ120 were ac-
quired for interpolation of poly(GP) levels using the
standard curve.
Generation of C9ORF72 depleted induced pluripotent
stem cell lines
Previously, we generated several patient-derived iPSC lines
from C9ORF72 ALS patients [18]. One of these lines was
transduced with a lentiviral vector (Sigma-Aldrich,
SHCLNV-NM-018325, clone TRCN0000148881) express-
ing a puromycin resistance gene and a small hairpin RNA
(shRNA) targeting all three C9ORF72 transcript variants.
Transduction of iPSCs (MOI = 3) was carried out in the
absence of polybrene. Selection was performed in the
presence of puromycin (1 μg/ml) for 10 days; surviving
colonies were expanded and used for motor neuronal
differentiation. Depletion of C9ORF72 RNAs was
confirmed by qPCR.
Motor neuron differentiation
Motor neuronal differentiation was performed according
to our previously published protocol [26]. Briefly, neural
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precursor spheres were differentiated from iPSC colonies
using neural induction medium and cultured in ultra-
low attachment flasks. Afterwards, spheres were seeded
onto poly-L-ornithine and laminin-coated plates with
neuronal induction medium and cultured for 4 weeks to
obtain terminally differentiated motor neurons.
DNA-RNA immunoprecipitation (DRIP)
The DRIP protocol was adapted from Loomis et al. [28]
with some modifications. Here, 5 × 106 cells were lysed
with 0.5% SDS and treated with 400 units of proteinase
K at 37 °C overnight. The next day, DNA extraction was
performed using standard phenol/chloroform/isopropa-
nol precipitation. Fifty micrograms of DNA were
digested with EcoR1, HindIII, BsrGI, and XbaI (20 units
each) at 37 °C for 1 h. Next, samples were incubated in
the presence of the S9.6 antibody (Kerafast ENH001) for
2 h at 4 °C with inversion. As a control, samples were
treated with 25 units of RNase H (ThermoFisher
Scientific #EN0201) for 6 h at 37 °C. Following DRIP,
DNA was precipitated with isopropanol and used for
quantitative PCR with primers amplifying a region
upstream (L/R: 5’AAGAGCAGGTGTGGGTTTAG / 5’G
AGTACTGTGAGAGCAAGTAGTG) and downstream
(L/R: 5’CTCAGAGCTCGACGCATTT / 5’CAATTCCA
CCAGTCGCTAGA) of the C9ORF72 hexanucleotide
repeat expansion.
C9ORF72 GGGGCC repeat methylation assessment
To measure C9ORF72 HRE methylation, we combined
HpaII methylation-sensitive restriction digest with the
repeat-primed PCR assay in the presence of 5% dimethyl
sulfoxide and complete substitution of 7-deaza-2-deoxy
GTP for dGTP as previously described [18]. PCR frag-
ments were analyzed using the ABI3730 DNA Analyzer
and GeneMapper software. The area under the curve
(AUC) values were calculated for peaks higher than 150
base pairs. The AUC of digested samples were normal-
ized to AUC of uncut controls to calculate the percent
DNA methylation of the HRE sequence.
DNA hydroxymethylation assessment
To quantify 5hmC and 5mC levels at the C9ORF72 pro-
moter, we utilized the EpiMark® 5-hmC and 5-mC
Analysis Kit (New England Biolabs E3317), according to
the manufacturer’s protocol as previously reported [18].
Briefly, 2 μg of genomic DNA was subjected to glycosyl-
ation by T4 β-glucosyltransferase, converting 5hmC to
5ghmC residues. Glucosylated DNA was then digested
with MspI or HpaII endonucleases for 6 h at 37 °C and
subsequently amplified by quantitative PCR using the
-313 bp primer set (L/R: 5’AGGAAAGAGAGGTGCGT
CAA / 5’TCCTAAACCCACACCTGCTC) and +104 bp
primer set (L/R: 5’AAATTGCGATGACTTTGCAG /
5’ACTGCAAACCCTGGTAGG), each of which spans
one CCGG MspI/HpaII restriction site.
Chromatin immunoprecipitation (ChIP)
Immunoprecipitation of H3K9me3 was performed as
we previously reported [26]. Briefly, 50 mg of brain tis-
sue was sliced into small pieces and crosslinked in 1%
formaldehyde for 10 min and quenched with 0.125 M
glycine for 5 min at room temperature. Sonication was
performed for 5 min using the Bioruptor UCD200 son-
ication system set to the high setting. Lysates were then
transferred to a tube containing Protein G Dynabeads
prepared with an anti-H3K9me3 antibody (Abcam
ab8898), or control rabbit IgG, and incubated overnight
at 4 °C with rotation. The following day, stringency
washes were performed and samples were re-suspended
in 150 μL elution buffer consisting of 1% SDS, 0.1 M
NaHCO3, 0.2 M NaCl and incubated at 65 °C over-
night. The next day, samples were de-crosslinked by
treatment with 50 μL proteinase K and incubated at
42 °C for 2 h. De-crosslinked genomic DNA was
isolated using the QiaQuick PCR purification kit
(Qiagen #28104) according to the manufacturer’s
instructions. Quantitative PCR was performed using
two primer sets: C9.A (L/R: 5’ACTCGCTGAGGGT
GAACAAG / 5’TCCTGAGTTCCAGAGCTTGC) and
C9.B (5’AAGAGCAGGTGTGGGTTTAG / 5’GAGTAC
TGTGAGAGCAAGTAGTG).
Results
Expression of the human C9ORF72 transgene decreases
while H3K9 tri-methylation increases in C9-BAC mice during
the first post-natal weeks
Tissue samples from mice of seven different age groups
were assessed in this study: post-natal week 0 (n = 5), 2
(n = 4), 7 (n = 5), 17 (n = 4), 30 (n = 9), 36 (n = 4) and
93 (n = 9). The activity and epigenetic status of the hu-
man C9ORF72 transgene was assessed by quantifying
levels of mRNAs and histone methylation within the
promoter of the human gene. First, we measured human
C9ORF72 mRNA levels in the neocortex of C9-BAC
mice across all age groups using quantitative real-time
(qPCR). Three primer sets were used to amplify different
human C9ORF72 mRNA transcript variants (V1, V2,
and V3) as well as three endogenous controls (beta-
actin, GAPDH and 18S). Due to the observed variability
in beta-actin expression levels across age groups
(Additional file 1: Figure S1A), we used the average
values of GAPDH and 18S for normalization. We found
that levels of all three C9ORF72 transcript variants are
significantly reduced, starting within the first post-natal
weeks of age (Fig. 1). To confirm our findings, we per-
formed digital droplet quantitative PCR (ddPCR) for
absolute quantification of the human C9ORF72 levels
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and observed a similar trend (Additional file 1:
Figure S1B). This observation suggests that partial
epigenetic repression of the C9ORF72 transgene in
the brain of post-natal C9-BAC mice is age-
dependent. Next, we utilized chromatin immunopre-
cipitation (ChIP) to isolate H3K9me3-bound DNA
fragments from brain samples of 0 and 7 weeks-old
C9-BAC mice. H3K9me3 is a repressive epigenetic
mark that negatively correlates with transcription
rates and is enriched within the promoter region of
expanded C9ORF72 alleles as compared to unex-
pended alleles [12, 26, 29]. Using two different pri-
mer sets (C9.A and C9.B), we found that H3K9me3
levels within the promoter of the human C9ORF72
transgene were significantly increased in the brain of
C9-BAC mice by week 7 (Fig. 1d). Increased
H3K9me3 indicates partial epigenetic repression of
the mutant gene locus occurs in the first post-natal
weeks of life.
DNA hypermethylation within the promoter of the human
C9ORF72 transgene occurs in a subset of C9-BAC mice,
similar to the human C9-ALS patient population
In about 30% of all C9-ALS cases, methylated CpG
dinucleotides within the C9ORF72 promoter occur more
frequently [13, 15]. This promoter hypermethylation is
associated with a modestly attenuated phenotype indi-
cating that epigenetic repression is clinically relevant
[16, 17]. To assess levels of DNA methylation within the
promoter of the C9ORF72 transgene, we extracted
DNA from the cortex of C9-BAC mice and performed
methylation-sensitive PCR as previously reported [26].
Interestingly, we found that in three adult mice, the
C9ORF72 promoter was hypermethylated, similar to
what occurs in a subset of human C9-ALS patients
(Fig. 2a). Similar to C9-ALS patients, C9ORF72 pro-
moter hypermethylation in C9-BAC mice was stable
across different brain regions (cortex and cerebellum)
and somatic tissues (blood and tail clippings) (Fig. 2b).
To confirm these findings, we utilized a secondary
method to assess DNA methylation. Using bisulfite py-
rosequencing, we measured DNA methylation across
eight different CpG dinucleotides located both up-
stream and downstream of the transcription start site
(TSS) of the human C9ORF72 promoter (Fig. 2c). Fur-
thermore, we have eliminated the possibility that in-
creased methylation levels are due to the abnormal
copy number of the human C9ORF72 transgene by
CNV analysis (Additional file 2: Figure S2). Our data
demonstrate that adult mice from the same age group
can have differential DNA methylation levels within the
C9ORF72 promoter, mirroring a phenomenon observed
in C9-ALS patients. To determine whether promoter
hypermethylation affects the production of toxic DPRs,
we next measured levels of glycine-proline (GP) repeat
proteins in the brains of three hypermethylated and
nine unmethylated C9-BAC mice (Fig. 2d). Our data in-
dicate that there is a trend towards decreased GP levels
Fig. 1 C9ORF72 transcription decreases while a repressive histone methylation mark increases in the brain of C9-BAC mice during the first post-natal
weeks. Values of human C9ORF72 in the BAC mouse cortex, normalized to the average of GAPDH and 18S, are shown for primers amplifying transcript
variants V1, V2, V3 (a); V1, V3 (b) and V2 (c). Age groups are indicated on the x-axis in weeks (wks). Mean and standard error of the mean (SEM) are
indicated by long and short bars respectively. For each primer set, a one-way analysis of variance was performed (p < 0.001). Bonferroni’s multiple
comparison test was performed between neonatal (0wks) and the rest of the age groups, significance is indicated by p < 0.05 * and p < 0.01 **.
H3K9me3 levels were assessed by chromatin immunoprecipitation in brain tissues from 0 to 7 week-old C9-BAC mice (n = 5). Two different primer sets
were used: C9.A and C9.B amplifying regions within the human C9ORF72 promoter. Relative enrichment of H3K9me3 was calculated by real-time PCR
amplification of immunoprecipitants (IP) relative to inputs and an IgG negative control IP, p < 0.01 ** (d)
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in hypermethylated mice. Nevertheless, further studies
with more animals are required to fully investigate the
effect of DNA hypermethylation at the C9ORF72 pro-
moter on DPR production in these mice. Notably, GP
levels in hypermethylated mice negatively correlated
with the DNA methylation percentile as determined by
bisulfite pyrosequencing analysis of 8 CpG dinucleo-
tides (Additional file 3: Figure S3). The goodness of fit
(R2) was similar for each of the 8 CpGs suggesting none
have a more prominent regulatory role than others.
Methylation of GGGGCC repeat expansion mutation
increases with age in C9-BAC mice
Previously, Xi et al. reported that the HRE itself is
methylated in every C9-ALS patient with the patho-
genic repeat number [30], indicating a protective cellu-
lar response. Interestingly, the authors argue that the
origin of DNA hypermethylation initiates within the
HRE, but in some individuals, methylation spreads
upstream to the promoter region. Therefore, we sought
to determine if HRE hypermethylation is recapitulated
in a C9-BAC mouse model of ALS. To quantitatively
assess DNA methylation levels at the HRE in C9-BAC
mice, we developed a novel assay that combines the
HpaII methylation-sensitive restriction digest, which
recognizes CCGG sequence, with repeat-primed PCR
and capillary electrophoresis (Fig. 3a). Given our find-
ing that expression of the human C9ORF72 transgene
decreases within the first weeks of life (Fig. 1), we
quantified DNA methylation of the HRE at 0, 2 and
7 weeks of age (Fig. 3b). We observed that HRE methy-
lation was present in all three age groups but increased
with age, reaching significance between 0 and 7 weeks.
Representative graphs from one animal per group are
shown in Fig. 3c. These findings suggest that methyla-
tion of cytosine residues within the HRE sequence
itself occurs within the first weeks of the C9-BAC
mouse lifespan.
Fig. 2 DNA hypermethylation at the expanded C9ORF72 promoter appears in a fraction of adult mice. Site-specific DNA methylation sensitive PCR
assessment of the human C9ORF72 promoter in the cortex of C9-BAC mice at seven time points, indicated in weeks (wks) of age. Two HhaI restriction
sites located at −215 and −109 base pairs from the transcriptional start site were interrogated; three hypermethylated animals are indicated by open
shapes (17wks square, 30wks triangle and 36wks circle). Assay controls (grey circles on right) include DNA isolated from post mortem brain tissues of ALS
patients with the hexanucleotide repeat expansion (C9+) with (me+) or without (me-) promoter hypermethylation, an unaffected healthy control (C9-)
individual, and synthetic DNA enriched (CTL Me 100%) or depleted of 5mC (CTL Me 0%). Values are plotted relative to the synthetic high control, which
is set to 100% (a). C9ORF72 promoter methylation assessment from brain cortex, cerebellum, blood and tail clippings of a 30 week old hypermethylated
mouse using HhaI methylation sensitive PCR (b). Bisulfite pyrosequencing of brain cortex from 17, 30 and 36 weeks old C9-BAC mice (n = 1 per age
group per methylation status) across 8 CpG dinucleotides within the human C9ORF72 promoter, positions relative to TSS are shown on the x-axis. Open
symbols indicate samples from hypermethylated (me+) animals, filled symbols are samples from unmethylated (me-) animals (c). Glycine-Proline DPR
assessment of whole brain tissue samples from three hypermethylated animals (open symbols) and representative unmethylated samples
(filled symbols) from 17, 30 and 36 week old C9-BAC mice (n = 3 per age group) (d)
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Hydroxymethylcytosine is observed at the expanded
C9ORF72 promoter in the brain of C9-BAC mice
We previously reported that 5-hydroxymethylcytosine
(5hmC), a stable intermediate of the DNA demethyla-
tion pathway, is a novel epigenetic feature of repeat
expansions mutations in Fragile X Syndrome and C9-
ALS [18, 31]. Here, we sought to determine whether
5hmC is present at the C9ORF72 promoter of
hypermethylated BAC mice as well. We performed
DNA hydroxymethylation assessment as previously de-
scribed [18, 31]. We found that similar to C9-ALS pa-
tients, hypermethylated C9-BAC mice show elevated
levels of 5hmC at the C9ORF72 promoter sites both
upstream and downstream of the TSS in the cortex
(Fig. 4a, b). Furthermore, we assessed peripheral tissues
from the 30 week-old hypermethylated mouse. We
found that 5hmC enrichment was unique to brain tis-
sues (Fig. 4c, d). This indicates more pronounced DNA
demethylation in the brain of hypermethylated C9-BAC
mice which is consistent with the highest abundance of
the global 5hmC levels occurring in the central nervous
system as compared to other tissue types, presumably
due to the higher ten-eleven-translocation (TET)
enzyme activity [32, 33].
DNA hypermethylation is acquired independently of RNA-
DNA hybrid formation at the C9ORF72 locus
We next sought to investigate one possible mechan-
ism of DNA methylation acquisition at the C9ORF72
promoter of ALS patients. By analogy to other repeat
expansion disorders, such as Fragile X Syndrome and
Freidriech’s Ataxia [21, 34], we hypothesized that
DNA-RNA hybrids or R-loops formed by an ex-
panded C9ORF72 transcript lead to epigenetic silen-
cing. In our previous report, we demonstrated that
iPSC lines from a hypermethylated ALS patient can
be used as a tool to investigate the acquisition of
DNA methylation at the C9ORF72 promoter [18]. In
particular, we showed that DNA methylation at the
C9ORF72 promoter is erased during iPSC generation
and then re-acquired during neuronal differentiation.
To determine whether C9ORF72 promoter DNA
hypermethylation occurs via DNA-RNA hybrid for-
mation, we created a stable iPSC line from a hyper-
methylated ALS patient expressing a small hairpin
RNA targeting all three C9ORF72 transcript variants
(shC9) or a scrambled control (shCTL). We reasoned
that disrupting R-loop formation by depleting
C9ORF72 mRNAs in iPSCs would prevent DNA
Fig. 3 Hexanucleotide (GGGGCC) repeat methylation increases with age in C9-BAC mice. An illustration of the HRE methylation assessment
method. For each sample, two repeat-primed PCR reactions are performed, one using DNA subjected to HpaII digest and one using uncut control
(UC). DNA methylation percentage is calculated based on the area under the curve values following capillary fragment analysis of HpaII digested
samples normalized to the uncut control sample (a). HRE methylation levels were assessed at 0 (n = 5), 2 (n = 4) and 7 (n = 5) weeks of age,
significance is indicated by *p < 0.05 (b). Representative electropherograms from 0 to 7 week old C9-BAC mouse brain cortex DNA treated with
HpaII as well as uncut control (c)
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hypermethylation upon neuronal differentiation, simi-
lar to what was previously shown in Fragile X Syn-
drome [34]. We generated stable iPSC cell lines
expressing either the shC9 or shCTL constructs then
differentiated the cells into motor neurons using our
previously published protocols [18]. We confirmed
efficient depletion of C9ORF72 in shC9 iPSC lines
using qPCR (Fig. 5a). We then confirmed efficient
disruption of R-loop formation at the C9ORF72 locus
in shC9 motor neurons using DNA-RNA
immunoprecipitation (DRIP) followed by qPCR with
primers to amplify regions upstream and downstream
the HRE (Fig. 5b, c). Finally, DNA methylation at the
C9ORF72 promoter in motor neurons was assessed
across 16 individual CpG dinucleotides using bisulfite
pyrosequencing (Fig. 5d). Patient-derived motor neu-
rons from an individual with the Fragile X Syndrome
that does not harbor C9ORF72 repeat expansion
were used as a negative control. Despite efficient
knockdown of C9ORF72 RNAs and disruption of R-
loops, we did not observe significant differences in
DNA methylation levels at the C9ORF72 promoter
between shC9 and shCTL motor neurons. These
results suggest that R-loops may not be required for
the acquisition of DNA hypermethylation associated
with the C9ORF72 HRE.
Discussion
Here we report that C9-BAC mice from Peters et al. [23]
recapitulate epigenetic perturbations seen in C9ORF72-
associated ALS and FTD patients. We observed enrich-
ment of the repressive epigenetic mark H3K9me3 in the
promoter of the human transgene, which corresponded
to decreased transcription rates. We also observed DNA
methylation within the HRE repeat sequence itself for all
mice tested and in three mice, this methylation had
spread to the promoter region. Our data show that
HRE-mediated epigenetic repression occurs during the
first few weeks after birth in C9-BAC mice and likely oc-
curs at about the time of birth in humans (2 weeks in
the mouse), although the unavailability of human tissues
makes this difficult to assess. It will be important to de-
termine whether epigenetic features of the HRE are
shared among different C9-BAC lines. Of particular
interest will be to determine whether phenotypic severity
is associated with levels of epigenetic repression, in cases
where a phenotype is observed, and whether the epigen-
etic repression is lost (even relatively) as animals con-
tinue to age and develop a clinical phenotype.
Our findings demonstrate that epigenetic features of
the HRE in humans are mirrored in the C9-BAC mouse,
and in some cases, appear at a similar levels and fre-
quencies. For example, DNA hypermethylation of the
Fig. 4 DNA demethylation is observed at the expanded C9ORF72 promoter distinctively in the brain. Two CpG dinucleotides located within MspI/
HpaII restriction sites at positions −313 and +104 base pairs from the C9ORF72 transcriptional start site were interrogated by 5-methylcytosine (5mC)
and 5-hydroxymethylcytosine (5hmC) sensitive PCR. The y-axis indicates percent 5hmC (black) and 5mC (grey) from brain cortex samples for a subset
of C9-BAC mice (a, b), error bars represent standard deviation, experiments were performed in duplicates (N = 2 from a single biological sample for
each age and methylation status). Assessment of 5hmC enrichment at two restriction sites across tissue types of a 30 week old hypermethylated
mouse are illustrated in c and d. Student’s t-test was performed to determine significance, indicated by p < 0.05 *
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HRE itself in C9 ALS/FTD patients occurs at a rate of
97% [30]. Using a quantitative assay to assess HRE methy-
lation, we found that all C9-BAC mice assessed exhibit
hypermethylation of the repeat sequence. This HRE
methylation increases with age, although P0 mice also
show elevated levels of methylation within the repeat.
These observations support the hypothesis that increased
levels of DNA methylation within the repeat precede pro-
moter hypermethylation and is a common feature of the
HRE that serves a protective role to impede transcription
across the mutation [16, 17, 30, 35]. The C9ORF72 pro-
moter hypermethylation on the other hand, is less com-
mon in C9-ALS patients, and is only observed in a
fraction (~30%) of individuals with a pathogenic repeat
number [13, 15]. Interestingly, we found that to be true
for C9-BAC mice as well, where only a small fraction of
the adults show DNA hypermethylation at the C9ORF72
promoter, across different tissues. This is particularly
poignant given the neuroprotective effect of the C9ORF72
promoter hypermethylation in vivo [17]. Hence we sug-
gest that it may be important to stratify C9-BAC mice
based on their epigenetic status while conducting pheno-
typic assessments and performing pre-clinical testing of
experimental therapeutics.
Despite increased levels of repressive histone and DNA
methylation marks, expanded C9ORF72 alleles sustain suf-
ficient transcriptional activity to produce toxic levels of
mutant RNAs and DPRs. We have recently identified en-
richment of 5hmC, an active DNA demethylation inter-
mediate, as a novel epigenetic alteration common to at
least two repeat expansion disorders: Fragile X Syndrome
and C9-ALS [18, 31]. Given the high abundance of 5hmC
at the C9ORF72 promoter of hypermethylated patients
and C9-BAC mice, we postulate that active DNA demeth-
ylation counteracts the protective hypermethylation of the
promoter. Active DNA demethylation is a process facili-
tated by the ten-eleven translocation (TET) family proteins
and acts as a switch between transcriptionally inactive and
active gene states [36]. Our data demonstrate that active
DNA demethylation is most pronounced in the brain of
C9-BAC mice, in concordance with the literature indicat-
ing that TET activity and global 5hmC levels are highest in
neurons [32, 37]. Future studies are warranted to investi-
gate the possibility of leveraging epigenetic equilibrium,
perhaps by using small molecules, in such a way that it fa-
vors DNA hypermethylation to more completely repress
the expanded locus. This would be hypothesized to reduce
the production of toxic products in C9-BAC mice.
Fig. 5. DNA methylation is acquired independently of RNA-DNA hybrid formation at the C9ORF72 locus. Relative quantification of all three
C9ORF72 transcript variants in iPSC-derived motor neurons stably expressing a C9ORF72-specifc shRNA (shC9) or a scrambled CTL (shCTL) (a).
DNA-RNA immunoprecipitation at the C9ORF72 promoter of shC9 and shCTL motor neurons, relative quantification was measured using two sets of
primers, designed upstream (b) and downstream (c) of the repeat expansion, RNase H treatment was performed prior to pull-down as a negative
control. DNA methylation levels at the C9ORF72 promoter were assessed using bisulfite pyrosequencing across 16 CpG dinucleotides; positions relative
to the transcription start site are indicated on the x-axis (d). Fragile X patient-derived iPSC-neurons (FXS) were used as a negative control. All experiments
were performed in duplicates (N = 2 from a single biological sample for each iPSC line examined). Significance is indicated by p < 0.05 * and p < 0.01 **
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The mechanism by which DNA hypermethylation is
established at the C9ORF72 promoter has been stud-
ied by our group and others [18, 29, 38]. These stud-
ies suggest that RNA-DNA hybrids or R-loops are
key mediators of epigenetic repression [39]. Recent
discoveries in other repeat expansion disorders,
including Fragile X Syndrome and Freidriech’s Ataxia
support this reasoning [21, 34]. Here we investigated
this possibility using iPSC-derived motor neurons, a
method that we have successfully utilized in our
previous report to model the acquisition of DNA
hypermethylation in C9-ALS [18]. We show that
despite their presence at the C9ORF72 promoter of
C9-ALS patient derived cells, reducing R-loop forma-
tion by depleting HRE RNAs is not sufficient to
prevent the acquisition of DNA hypermethylation.
Future studies could investigate alternative mecha-
nisms leading to the epigenetic repression of HRE
promoters. Though we did not address this issue
here, it would also be interesting to see whether
C9ORF72 knockdown in C9-BAC mice will have any
effect on the levels of DNA methylation associated
with the expanded locus.
Conclusions
We have determined that epigenetic perturbations
seen in C9-ALS patients are also observed in C9-BAC
mice and that R-loops are unlikely to be initiators of
DNA methylation at the expanded C9ORF72 locus.
Since many repeat expansion mutations, including
C9-ALS, have an epigenetic component that is
directly linked to pathology, our observations are of
significant importance for understanding the mechan-
ism of disease and are of consequence for therapeutic
development efforts utilizing C9-BAC mouse models.
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